New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad’s Prolaris® Biopsy Test in Localized Prostate Cancer
Myriad Genetics announced the publication of the largest meta-analysis to date for its Prolaris Biopsy Test in Clinical Genitourinary Cancer. The analysis pooled data from 14 studies involving 8,478 patients, demonstrating that the test provides independent prognostic information for metastasis and prostate cancer-specific mortality beyond standard clinical risk groups.
Key figures
- Studies pooled
- 14
- Patients analyzed total
- 8478
- Patients individual data
- 7924
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.